MRNA - Moderna Inc Market Cap to Sales Volume

Moderna, Inc. (MRNA) is accelerating vaccine development through AI algorithms and robotic manufacturing. The market capitalization-to-revenue ratio on the GURU.Markets service reflects this trend, with the indicator reaching 37.10. While the digitalization of mRNA synthesis reduces testing timelines, the decline in COVID-related revenues is forcing the company to rapidly deploy new respiratory products to maintain its financial health.

Moderna Corp (MRNA): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Metric breakdowns and analytics for Moderna Corp (MRNA)

- market price and analyst price targets:

Stock Quotes modernatx.com|MRNA - Consensus Target

- market capitalization statistics:

Market Value Moderna Corp|MRNA - Enterprise Value

- book capitalization information:

Net Assets per Share Moderna|MRNA - Company Book Value|Market-to-Book Ratio modernatx.com|MRNA - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

MRNA - Net Profit|Expected Net Profit Moderna, Inc.|MRNA - Price to Earnings Ratio|Future Price to Earnings Multiple Moderna Inc|MRNA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Moderna Corp|MRNA - Operating profit EBITDA|Net earnings per share (EPS TTM) Moderna|MRNA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months modernatx.com|MRNA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Moderna, Inc.

- total revenue and sales volume data:

MRNA - Company Revenue|Company Revenue Forecast modernatx.com|MRNA - P/S Multiple|Forward Price-to-Revenue Multiple Moderna Corp

Fundamental company analysis:MRNA (modernatx.com)

Investors are assessing the potential of Moderna, Inc. (MRNA) through the market value of a single dollar of revenue, which is critical for capital-intensive biotechnology companies. By analyzing the price-to-sales ratio, you determine the extent of the premium paid for the scalable mRNA platform, where a high valuation is justified by the uniqueness of patents and the barriers to entry for competitors into this technological circuit.

Competitors of Moderna, Inc.